FIELD: biotechnologies.
SUBSTANCE: disclosed are a bispecific antibody that specifically binds to EpCAM and CD3, comprising an antigen-binding domain specifically binding to EpCAM and an antigen-binding domain specifically binding to CD, nucleic acid composition for preparing it, a host cell for preparing the bispecific antibody, a pharmaceutical composition for preventing or treating EpCAM-positive cancer. In addition, there are presented a kit for preventing or treating cancer and a method for preventing or treating EpCAM-positive cancer involving administering a therapeutically effective amount of the bispecific antibody into a subject.
EFFECT: invention can be used for treating malignant new growths in a subject.
14 cl, 6 dwg, 9 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BISPECIFIC ANTIBODIES TO Vβ17/CD123 | 2020 |
|
RU2831786C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
